Literature DB >> 2060545

Disposition of oral quinine in acute falciparum malaria.

W Supanaranond1, T M Davis, S Pukrittayakamee, K Silamut, J Karbwang, P Molunto, L Chanond, N J White.   

Abstract

Plasma quinine concentrations following oral quinine sulphate 10 mg salt/kg have been measured by HPLC in 15 adult Thai patients with uncomplicated falciparum malaria. In 10 of the same patients the study was repeated in convalescence. In acute malaria plasma concentrations were approximately 50% higher than in convalescence; the mean acute peak plasma quinine concentration was 8.4 mg.l-1 compared to 5.7 mg.l-1 in convalescence. There was considerable variation in the rate of drug absorption, particularly in acute malaria. The mean time to peak plasma concentration was 5.9 h in acute malaria and 3.2 h in convalescence. The apparent clearance of oral quinine (CL/f) during the illness was 1.51 ml.kg-1.min-1, which was significantly lower than in convalescence--2.67 ml.kg-1.min-1. Estimated free quinine clearance was also lower in the acute phase: 30.6 compared to 49.0 ml.kg-1.min-1 in convalescence. Mean (SD) plasma protein binding of quinine was 94.7% in acute malaria and 92.8% in convalescence. Binding was significantly correlated with the plasma concentration of alpha 1 acid glycoprotein (r = 0.5), which was significantly higher in the acute phase; 1.48 g.l-1 compared to 1.05 g.l-1 during convalescence. Oral quinine sulphate was well absorbed in uncomplicated falciparum malaria. High blood concentrations following the administration of oral quinine in acute malaria are probably related to increased plasma protein binding, lower apparent volume of distribution, and a reduction in its systemic clearance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060545     DOI: 10.1007/bf00315138

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. III. THE PHYSIOLOGICAL DISPOSITION AND ANTIMALARIAL ACTIVITY OF THE CINCHONA ALKALOIDS.

Authors:  J V Taggart; D P Earle; R W Berliner; C G Zubrod; W J Welch; N B Wise; E F Schroeder; I M London; J A Shannon
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

2.  Determination of mefloquine in biological fluids using high performance liquid chromatography.

Authors:  J Karbwang; P Molunto; K Na Bangchang; D Bunnag
Journal:  Southeast Asian J Trop Med Public Health       Date:  1989-03       Impact factor: 0.267

Review 3.  The pharmacokinetics of quinine and quinidine in malaria.

Authors:  N J White
Journal:  Acta Leiden       Date:  1987

Review 4.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Quantification of quinine in human serum by high-performance liquid chromatography.

Authors:  M Edstein; J Stace; F Shann
Journal:  J Chromatogr       Date:  1983-12-09

6.  The bioavailability of quinine.

Authors:  J C Garnham; K Raymond; E Shotton; P Turner
Journal:  J Trop Med Hyg       Date:  1976-12

7.  Relative bioavailability of the hydrochloride, sulphate and ethyl carbonate salts of quinine.

Authors:  A Jamaludin; M Mohamad; V Navaratnam; K Selliah; S C Tan; W H Wernsdorfer; K H Yuen
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

8.  Quinine disposition during malaria and during induced fever.

Authors:  G M Trenholme; R L Williams; K H Rieckmann; H Frischer; P E Carson
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

9.  Pharmacokinetics of quinine in children.

Authors:  F Shann; J Stace; M Edstein
Journal:  J Pediatr       Date:  1985-03       Impact factor: 4.406

10.  Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria.

Authors:  N J White; S Looareesuwan; D A Warrell; M J Warrell; D Bunnag; T Harinasuta
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

View more
  19 in total

1.  Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.

Authors:  Julius O Soyinka; Cyprian O Onyeji; Sharon I Omoruyi; Adegbenga R Owolabi; Pullela V Sarma; James M Cook
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 2.  Antimalarial pharmacokinetics and treatment regimens.

Authors:  N J White
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 3.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria.

Authors:  K Silamut; P Molunto; M Ho; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

5.  Physiological Regulation of Drug Metabolism and Transport: Pregnancy, Microbiome, Inflammation, Infection, and Fasting.

Authors:  Edward T Morgan; Joseph L Dempsey; Sylvie M Mimche; Tracey J Lamb; Supriya Kulkarni; Julia Yue Cui; Hyunyoung Jeong; Angela L Slitt
Journal:  Drug Metab Dispos       Date:  2018-03-07       Impact factor: 3.922

6.  The reproducibility of quinine bioavailability.

Authors:  G Paintaud; G Alván; O Ericsson
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

Review 7.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

8.  Pharmacokinetics of quinine in African patients with acute falciparum malaria.

Authors:  C P Babalola; O O Bolaji; F A Ogunbona; A Sowunmi; O Walker
Journal:  Pharm World Sci       Date:  1998-06

9.  The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly.

Authors:  J R Dyer; T M Davis; C Giele; T Annus; P Garcia-Webb; J Robson
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

10.  Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels.

Authors:  Ingo Staudacher; Claudius Illg; Sam Chai; Isabelle Deschenes; Sebastian Seehausen; Dominik Gramlich; Mara Elena Müller; Teresa Wieder; Ann-Kathrin Rahm; Christina Mayer; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-14       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.